Radiopharm Theranostics Statistics
Total Valuation
RADX has a market cap or net worth of $32.61 million. The enterprise value is $20.52 million.
| Market Cap | 32.61M |
| Enterprise Value | 20.52M |
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025.
| Earnings Date | Feb 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RADX has 2.17 billion shares outstanding. The number of shares has increased by 26.36% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.17B |
| Shares Change (YoY) | +26.36% |
| Shares Change (QoQ) | +25.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.56B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30
| Current Ratio | 1.30 |
| Quick Ratio | 1.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -54.95 |
Financial Efficiency
Return on equity (ROE) is -131.49% and return on invested capital (ROIC) is -60.55%.
| Return on Equity (ROE) | -131.49% |
| Return on Assets (ROA) | -30.04% |
| Return on Capital (ROIC) | -60.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RADX has paid $64,294 in taxes.
| Income Tax | 64,294 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.85 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 59,920 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RADX had revenue of $1.31 million and -$31.99 million in losses. Loss per share was -$0.08.
| Revenue | 1.31M |
| Gross Profit | -13.11M |
| Operating Income | -23.57M |
| Pretax Income | n/a |
| Net Income | -31.99M |
| EBITDA | -21.49M |
| EBIT | -23.57M |
| Loss Per Share | -$0.08 |
Balance Sheet
| Cash & Cash Equivalents | 12.39M |
| Total Debt | n/a |
| Net Cash | 12.39M |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 18.25M |
| Book Value Per Share | 0.04 |
| Working Capital | 3.52M |
Cash Flow
| Operating Cash Flow | -15.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | -14.36M |
| FCF Per Share | -$0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,803.82% |
| Pretax Margin | -2,443.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RADX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.36% |
| Shareholder Yield | -26.36% |
| Earnings Yield | -98.10% |
| FCF Yield | -44.05% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RADX has an Altman Z-Score of -3.29 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.29 |
| Piotroski F-Score | 2 |